TNF-SAM2

Drug Profile

TNF-SAM2

Alternative Names: Recombinant tumour necrosis factor-TNF-SAM2

Latest Information Update: 30 Aug 2002

Price : $50

At a glance

  • Originator Unknown
  • Developer Nonindustrial source
  • Class Antineoplastics; Tumour necrosis factors
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 02 Jun 1999 A clinical study has been added to the adverse events, pharmacodynamics and therapeutic trials sections
  • 02 Jun 1999 A clinical study has been added to the therapeutic trials section
  • 05 May 1999 A clinical study has been added to the therapeutic trials, adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top